MedMira Inc. continues its North-American expansion plan

HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial Operations, effective immediately. Ms. Crenshaw's addition strengthens MedMira's leadership team as the company targets significant growth across its commercial portfolio.

Ms. Crenshaw brings over 25 years of experience in Clinical Diagnostics, with a background in Business Development, Sales, and Marketing in the United States, Canada, and global markets. Ms. Crenshaw holds a MBA in Business Administration and started as Global Business Development Manager with Roche Molecular Diagnostics. At Roche she focused on the COBAS TaqMan HIV, HCV, HBV and Transplantation product portfolios. After she held key leadership roles at Cepheid, Bio-Rad Laboratories, Randox Laboratories, Grifols Diagnostics, and her latest position as National Director of Business Development, Clinical Diagnostics for Thomas Scientific. Her expertise spans product development, strategic account management, and federal contracts, making her an invaluable asset as MedMira continues to expand its market share in North America.

"Nicole's wealth of experience in the clinical diagnostics industry, particularly her expertise in navigating complex federal and government contracts, will play a critical role in our expansion strategy," said Hermes Chan, CEO of MedMira. "Partnering with Ms. Rene Bell, our VP of Business Development, Nicole's leadership will be vital in executing our growth plan and expanding our impact in the North American market, particularly in the STI diagnostics field."

Ms. Crenshaw holds an MBA in Business Administration and has a proven track record of delivering growth in diverse market environments, particularly through strategic partnerships with Group Purchasing Organizations, Health Networks, and federal accounts. At MedMira, she will oversee federal and major contracts with distributors and large clients, driving the company's commercial growth strategy and execution.

The appointment of Ms. Crenshaw further aligns with MedMira's goal to expand market share and accelerate commercialization efforts for its innovative diagnostic products. The company remains committed to building a strong leadership team to maximize market opportunities and deliver increased value to shareholders.

About MedMira

MedMira is a leading developer and manufacturer of Rapid Vertical Flow^® diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company's tests are sold globally under the REVEAL^®, REVEALCOVID-19^®,Multiplo^® and Miriad^® brands. Based on its patented Rapid Vertical Flow^® Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contact

Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com

SOURCE: MedMira, Inc.